secwatch.observer — SEC 8-K summary
======================================

Issuer:     GridAI Technologies Corp. (GRDX)
CIK:        0001604191
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0001104659-24-098369
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entero Therapeutics signs LOI to license clinical trial compliance platform from DataVault Holdings
--------------------------------------------------------------------------------

- Binding LOI for exclusive worldwide license to QOLPOM and FotoDigm clinical trial software from DataVault Holdings.
- Consideration: $250,000 in convertible preferred shares priced at 180% of 5-day VWAP plus single-digit royalties on net sales.
- Deal contingent on Entero securing at least $500,000 strategic investment; target up to $3M.
- License intended to support Entero's planned Phase 3 latiglutenase trial for celiac disease and other GI indications.
- Right of first refusal to fully acquire the assets; closing targeted by end of September 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924098369/0001104659-24-098369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924098369/tm2423688d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-098369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer